跳至主要内容
临床试验/KCT0000542
KCT0000542尚未招募未知

Stereotactic ablative radiotherapy for hepatocellular carcinoma with major portal vein invasion: A phase II study

Korea Institute of Radiological & Medical Sciences0 个研究点目标入组 28 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
18(Year) 至 o Limit(—)
性别
All

入选标准

  • 1. Male or female patients =18 years of age
  • 2. Eastern Cooerative Oncology Group performance status 0 or 1
  • 3. HCC with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
  • 4. Cirrhotic status of Child Pugh class A or B7
  • 5. Patients can have extra-hepatic disease; provided the hepatic disease is the highest burden, the extra-hepatic disease is low burden and potentially treatable with radiotherapy, chemotherapy and target agent etc; patient survival is expected to be at least 6 months.
  • 6. Patient or gaurdian must be able to provide verbal and written informed consent

排除标准

  • 1. Prior trans-arterial chemo-embolization =4 after diagnosis of major portal vein tumor thrombosis
  • 2. Severe complication caused by liver cirrhosis eg. variceal bleeding, poorly controlled ascites, hepatic encephalopathy)
  • 3. Uncontrolled inter-current illness except liver cirrhosis

研究者

相似试验